PubMed Health⌕ Search

PubMed · 8358249

Declining bone loss rate variability with increasing follow-up time.

Abstract

Bone loss rates are believed to vary substantially among post-menopausal women. The belief, however, might be largely based upon comparisons of loss rates measured with considerable error. This issue arises because the precision of the bone mass instrumentation (1-2% errors in measuring bone mass) is similar in magnitude to the loss rate (typically 1-2% of bone mass per year). The 'true' variability in loss rates, however, can be estimated by adjusting for instrument errors. An equation is presented which estimates the true variability in loss rates from a study sample. The adjustment was examined using a cohort of post-menopausal, Japanese-American women living in Hawaii. The study examined the calcaneus, distal, and proximal radius sites. The results suggest that measurement errors did not markedly inflate the bone loss variability. Even after adjustment for measurement errors considerable variability in loss rates remained. The variability was examined for various follow-up durations. Both the observed and adjusted loss rates had smaller standard deviations over long intervals than over short intervals. This result suggests that the more extreme rates of change in bone mass over a year or two were often not sustained. The implications of this finding for sample size calculations in longitudinal studies are examined. The results also indicate that the length of follow-up and instrument precision should be taken into consideration when comparing the proportion of fast losers between populations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Y F He, J W Davis, P D Ross, R D Wasnich. 1993. Declining bone loss rate variability with increasing follow-up time.. https://doi.org/10.1016/s0169-6009(08)80014-1

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A repeated measures concordance correlation coefficient.

The concordance correlation coefficient is commonly used to assess agreement between two raters or two methods of measuring a response when the data are measured on a continuous scale. However, the situation may arise in which repeated measurements are taken for each rater or method, e.g. longitudinal studies in clinical trials or bioassay data with subsamples. This paper proposes a coefficient for measuring agreement between two raters or two methods of measuring a response in the presence of repeated measurements. We illustrate the methodology with examples comparing (1) 1-hr versus 2-hr blood draws for measuring cortisol in an asthma clinical trial and (2) two measurements of percentage body fat, from skinfold calipers and dual energy X-ray absorptiometry.

Absorptiometry, Photon↗

Crystallization and preliminary X-ray analysis of a domain in the Runx2 transcription factor that interacts with the 1alpha,25 dihydroxy vitamin D3 receptor.

The Runx2 transcription factor is a key regulator of osteoblast differentiation. In response to 1alpha,25 dihydroxy vitamin D3, Runx2 may interact with the 1alpha,25 dihydroxy vitamin D3 receptor (VDR) in the promoter of target genes, producing a synergic activation of their transcription. Previous studies have suggested that the motifs responsible for the VDR-Runx2 interaction are contained within the 230-361 domain of Runx2. In this work, we confirmed by GST-pull down that Runx2(I(209-361)) is sufficient to interact with the VDR. To obtain structural information, GST-Runx2(I(209-361)) protein was overexpressed in Escherichia coli, purified and crystallized using the hanging-drop vapor-diffusion method and polyethyleneglycol as a precipitant. The crystals were found to diffract to a maximum resolution of 2.7 A and a complete data set to a 3.3 A resolution was collected and analyzed. The crystals belong to the tetragonal system, with a space group P4 and unit-cell parameters of a = b = 90.8, and c = 57.2 A. The presence of a monomer of the recombinant GST-Runx2(I(209-361)) in the asymmetric unit gives a V(M) of 2.7 A(3) Da(-1) and a solvent content of 54.8%.

Absorptiometry, Photon↗

Quantifying the treatment effect explained by markers in the presence of measurement error.

Surrogate markers or intermediate markers are important in identifying subjects with high risk of a serious disease or for monitoring disease progression of a subject on treatment. Quantifying the proportion of treatment effect (PTE) explained by markers has been studied extensively. Due to reasons such as biological variation, limited machine precision, etc. markers are generally measured with error. The estimated PTE ignoring the measurement error could be biased, which may lead to incorrect conclusions. In this article, we adjust for the measurement error using regression calibration to construct a less biased estimator of excess relative odds, a quantity to measure the treatment effect explained by markers. The method is applied to data from a clinical study in osteoporosis.

Absorptiometry, Photon↗